Ahmet Cihat GENÇ, Mehmet KÖROĞLU, Seyyid Bilal AÇIKGÖZ, Hamad DHEİR, Oğuz KARABAY, Ali Fuat ERDEM, Savaş SİPAHİ, Aysel TOÇOĞLU, Melike BEKTAŞ, Fuldem MUTLU

Characteristics and mortality determinants of COVID-19 patients undergoing hemodialysis

Background/aim: The COVID-19 infection, which started in Wuhan City, China, in December 2019, turned into a pandemic in a very short time, affecting mainly the elderly and those with serious chronic illnesses. COVID-19 infections have been observed to have a high mortality rate, especially in patients undergoing maintenance hemodialysis. Materials and methods: Forty-two patients over 18 years of age who underwent a maintenance hemodialysis program at our unit, who tested positive for COVID-19 by PCR from nasopharyngeal swabs, and/or who were observed to have disease-related signs in their CTs were included in the study. Results: In this study, 23 of 42 patients receiving hemodialysis support in our clinic were included. The median age was 67 years old (min: 35; max: 91 years), and all of our patients had primary hypertension and other comorbidities. Their clinical evaluation showed that dry cough (47.8%) and shortness of breath (47.8%) were the most common symptoms. Fever was less pronounced (30.4%). The median time from the onset of symptoms to hospitalization was 1 day (min: 0; max:), and the time from hospitalization to death was 18 days (min: 1; max: 22). Transfer from the inpatient ward to the ICU took a median of 7 days (min: 1; max: 13). Among the 23 patients, 3 died during follow-up, and 20 were discharged with full recovery. Baseline ferritin, procalcitonin levels, and CRP/albumin rates were higher, and neutrophil/lymphocyte levels were lower in patients who eventually died. In these patients, despite being nonsignificant, there were more diabetic patients, and the D-dimer levels were higher than 1000 ugFEU/L. Conclusion: The COVID-19 infection is associated with increased mortality in chronic kidney diseases patients. Despite being nonsignificant, there was a trend towards increased mortality in patient with diabetes, D-dimer levels >1000 ugFEU/L, higher ferritin and prokalsitonin levels, an increased CRP/albumin ratio, and a lower neutrophil/lymphocyte ratio.Key words: Chronic renal failure, hemodialysis, COVID-19

PDF

___

1. Ma Y, Diao B, Lv X, Zhu J, Liang W et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. MedRxiv 2020. doi:10.1101/2020.02.24.20027201
2. Lu R, Zhao X, Li J, Niu P, Yang B et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224): 565-574. doi:10.1016/S0140-6736(20)30251-8
3. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D et al. Excerpts from the US renal data system 2009 annual data report. American Journal of Kidney Diseases 2011; 57 (1): A8. doi:10.1053/j.ajkd.2009.10.009
4. Ikizler TA. COVID-19 and Dialysis units: what do we know now and what should we do? American Journal of Kidney Diseases 2020; 76 (1): 1-3.doi:10.1053/j.ajkd.2020.03.008
5. Li J, Xu G. Lessons from the experience in Wuhan to reduce risk of COVID-19 infection in patients undergoing long-term hemodialysis. Clinical Journal of the American Society of Nephrology 2020; 15 (5): 717-719. doi:10.2215/CJN.03420320
6. Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiology Reviews 2007; 20 (4): 660-694. doi:10.1128/CMR.00023-07
7. Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery 2020; 76: 71-76. doi:10.1016/j.ijsu.2020.02.034
8. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections 2020; 9 (1): 221-236. doi:10.1080/22221751.2020.1719902
9. Dong X, Cao Y, Lu X, Zhang J, Du H et al. Eleven faces of coronavirus disease 2019. Allergy 2020; 75 (7): 1699–1709. doi:10.1111/all.14289
10. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 2020; 109 (102433). doi:10.1016/j. jaut.2020.102433
11. Ai T, Yang Z, Hou H, Zhan C, Chen C et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020; 296: E32-E40. doi:10.1148/radiol.2020200642
12. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7
13. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062. doi:10.1016/S0140-6736(20)30566-3
14. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323 (18): 1775-1776. doi:10.1001/ jama.2020.4683
15. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH et al. The novel coronavirus 2019 epidemic and kidneys. Kidney International 2020; 97 (5): 824-828. doi:10.1016/j.kint.2020.03.001
16. Tang N, Bai H, Chen X, Gong J, Li D et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis 2020; 18 (5): 1094-1099. doi:10.1111/jth.14817